1-(2-broMo-4-chlorophenyl)cyclopropanaMine hcl
|
- $509.6 - $4434
- Product name: 1-(2-broMo-4-chlorophenyl)cyclopropanaMine hcl
- CAS: 1204580-93-7
- MF: C9H9BrClN
- MW: 246.53
- EINECS:
- MDL Number:MFCD14525461
- Synonyms:1-(2-Bromo-4-chlorophenyl)cyclopropylamine;1-(2-broMo-4-chlorophenyl)cyclopropanaMine hcl;1-(2-Bromo-4-chlorophenyl)cyclopropan-1-amine;Cyclopropanamine, 1-(2-bromo-4-chlorophenyl)-
4 prices
Selected condition：
Brand
- Alichem
- Crysdot
Package
- 250mg
- 1g
- 5g
- ManufacturerAlichem
- Product number1204580937
- Product description1-(2-Bromo-4-chlorophenyl)cyclopropylamine
- Packaging250mg
- Price$509.6
- Updated2021-12-16
- Buy
- ManufacturerAlichem
- Product number1204580937
- Product description1-(2-Bromo-4-chlorophenyl)cyclopropylamine
- Packaging1g
- Price$1273.02
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD12174055
- Product description1-(2-Bromo-4-chlorophenyl)cyclopropylamine 95+%
- Packaging1g
- Price$1144
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD12174055
- Product description1-(2-Bromo-4-chlorophenyl)cyclopropylamine 95+%
- Packaging5g
- Price$4434
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Alichem | 1204580937 | 1-(2-Bromo-4-chlorophenyl)cyclopropylamine | 250mg | $509.6 | 2021-12-16 | Buy |
| Alichem | 1204580937 | 1-(2-Bromo-4-chlorophenyl)cyclopropylamine | 1g | $1273.02 | 2021-12-16 | Buy |
| Crysdot | CD12174055 | 1-(2-Bromo-4-chlorophenyl)cyclopropylamine 95+% | 1g | $1144 | 2021-12-16 | Buy |
| Crysdot | CD12174055 | 1-(2-Bromo-4-chlorophenyl)cyclopropylamine 95+% | 5g | $4434 | 2021-12-16 | Buy |
Properties
Boiling point :297.7±40.0 °C(Predicted)
Density :1.626±0.06 g/cm3(Predicted)
pka :7.03±0.20(Predicted)
Density :1.626±0.06 g/cm3(Predicted)
pka :7.03±0.20(Predicted)
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|